Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome

Hematologic responses to hypomethylating agents are often delayed in patients with myelodysplastic syndrome or acute myeloid leukemia. Fetal hemoglobin is a potential novel bio-marker of response: recently, we demonstrated that a high fetal hemoglobin level prior to decitabine treatment was associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Stomper, Julia, Ihorst, Gabriele, Suciu, Stefan, Sander, Philipp N., Becker, Heiko, Wijermans, Pierre W., Plass, Christoph, Weichenhan, Dieter, Bissé, Emmanuel, Claus, Rainer, Lübbert, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312014/
https://www.ncbi.nlm.nih.gov/pubmed/30171030
http://dx.doi.org/10.3324/haematol.2017.187278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312014/
https://www.ncbi.nlm.nih.gov/pubmed/30171030
http://dx.doi.org/10.3324/haematol.2017.187278

Ejemplares similares